Sugi Predict

Sugi Predict / Compounds / SCHEMBL906764

SCHEMBL906764

SCHEMBL906764

CC(C)(F)c1cccc(Br)n1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 1/20 0.36
▸ GABRG2 P18507 1/20 0.36
▸ GABRB3 P28472 1/20 0.36
▸ GABRA3 P34903 1/20 0.36
▸ PGK1 P00558 1/20 0.35
▸ PGK2 P07205 1/20 0.35
▸ IDH1 O75874 2/20 0.35
▸ IDH2 P48735 1/20 0.35
▸ HTR7 P34969 2/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ ADRB1 P08588 1/20 0.33
▸ CYP3A4 P08684 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ GRM5 P41594 1/20 0.30
▸ P2RX7 Q99572 1/20 0.30
▸ IRAK4 Q9NWZ3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041313 1.00 GABRA1 (0.36) GABRA1GABRG2GABRB3GABRA3PGK1
SCHEMBL1437359 0.87 IDH1 (0.37) GABRA1GABRG2GABRB3GABRA3PGK1
SCHEMBL31078226 0.87 IDH1 (0.37) GABRA1GABRG2GABRB3GABRA3PGK1
SCHEMBL5646151 0.87 GABRA1 (0.36) GABRA1GABRG2GABRB3GABRA3PGK1
SCHEMBL21296390 0.83 GABRA1 (0.34) GABRA1GABRG2GABRB3GABRA3PGK1
SCHEMBL534247 0.82 HTR7 (0.35) GABRA1GABRG2GABRB3GABRA3IDH1
SCHEMBL955898 0.82 PGK1 (0.38) GABRA1GABRG2GABRB3GABRA3PGK1
SCHEMBL37428 0.82 GABRA1 (0.47) GABRA1GABRG2GABRB3GABRA3PGK1
SCHEMBL29427057 0.82 HTR7 (0.35) GABRA1GABRG2GABRB3GABRA3IDH1
SCHEMBL2757632 0.82 HTR7 (0.35) GABRA1GABRG2GABRB3GABRA3IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 — — US disclosed
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 — — US disclosed
EP-4554938-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 — — EP disclosed
EP-4522612-A1 TYK2 INHIBITORS Biogen MA Inc. (US) 2025-03-19 — — EP disclosed
US-12042495-B2 MAP4K1 inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2024-07-23 — — US disclosed
WO-2024015497-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2024-01-18 — — WO disclosed
WO-2023220046-A1 TYK2 INHIBITORS BIOGEN MA INC. (US) 2023-11-16 — — WO disclosed
US-20230140954-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-05-11 — — US disclosed
US-20230140954-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-05-11 — — US disclosed
US-20230140954-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-05-11 — — US disclosed
WO-2019074979-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF GIRAFPHARMA, LLC (US) 2019-04-18 — — WO disclosed
WO-2019074979-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF GIRAFPHARMA, LLC (US) 2019-04-18 — — WO disclosed
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-04-11 — — US disclosed
CN-101959883-B 3-indazolyl-4-pyridylisothiazoles LILLY CO ELI 2013-01-30 — — CN disclosed
EP-2276759-B1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES LILLY CO ELI (US) 2011-10-19 — — EP disclosed
US-7932274-B2 3-indazolyl-4-pyridylisothiazoles ELI LILLY AND COMPANY (US) 2011-04-26 — — US disclosed
EP-2276759-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES Eli Lilly & Company (US) 2011-01-26 — — EP disclosed
CN-101959883-A 3-indazolyl-4-pyridylisothiazoles LILLY CO ELI 2011-01-26 — — CN disclosed
US-20090253750-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES ELI LILLY AND COMPANY 2009-10-08 — — US disclosed
WO-2009123855-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES ELI LILLY AND COMPANY (US) 2009-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 GABRA1 1258/4885GABRG2 1041/4885GABRB3 1571/4885
US-20090253750-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES CYP3A4, IPO4, JAK3 GABRA1 2128/4885GABRG2 2847/4885GABRB3 2134/4885
US-20230140954-A1 MAP4K1 INHIBITORS MAP4K1, MAP4K4, MAP4K2 GABRA1 2995/4885GABRG2 2352/4885GABRB3 2859/4885
US-12042495-B2 MAP4K1 inhibitors MAP4K1, MAP4K4, MAP4K2 GABRA1 2995/4885GABRG2 2352/4885GABRB3 2859/4885
US-20190106427-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF WEE1, WEE2, NME1 GABRA1 4320/4885GABRG2 4221/4885GABRB3 4126/4885
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 GABRA1 1147/4885GABRG2 1159/4885GABRB3 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.